Merck, Inc.
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05382325
- Locations
- 🇮🇱
Rambam Health Care Campus-Oncology ( Site 0021), Haifa, Israel
🇮🇱Sheba Medical Center-ONCOLOGY ( Site 0020), Ramat Gan, Israel
🇳🇱Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037), Utrecht, Netherlands
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05347225
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital-hematology department ( Site 1002), Guangzhou, Guangdong, China
🇨🇳SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007), Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital-hematology department ( Site 1003), Zhengzhou, Henan, China
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05342636
- Locations
- 🇧🇷
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil
🇫🇷Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France
🇫🇷Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05335005
- Locations
- 🇮🇱
Hadassah Medical Center-Clinical Reaserch Unit ( Site 0002), Jerusalem, Israel
🇷🇴ARENSIA Exploratory Medicine-Clinical Nephrology Hospital "Carol Davila" ( Site 0001), București, Bucuresti, Romania
🇺🇸Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, United States
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05319730
- Locations
- 🇨🇱
Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. De Santiago, Chile
🇮🇹IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 32, Meldola, Emilia-Romagna, Italy
🇨🇳Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05314023
- Locations
- 🇨🇳
Center for Disease Control and Prevention of Rong An ( Site 0006), Liuzhou, Guangxi, China
🇨🇳Santai County Center for Disease Control and Prevention ( Site 0001), Mianyang, Sichuan, China
🇨🇳Liucheng County Centers for Disease Control and Prevention ( Site 0005), Liuzhou, Guangxi, China
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 784
- Registration Number
- NCT05298423
- Locations
- 🇨🇳
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
🇨🇳Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
🇨🇳The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 168
- Registration Number
- NCT05289271
- Locations
- 🇩🇪
Private Practice - Dr. Petri, Kinderarztpraxis ( Site 0056), Huerth, Nordrhein-Westfalen, Germany
🇩🇪Gemeinschaftspraxis Dres. Adelt, Mettlich-Lambrecht und Denneberg ( Site 0053), Bramsche, Niedersachsen, Germany
🇩🇪Kinderärztliche Gemeinschaftspraxis ( Site 0057), Wolfsburg, Niedersachsen, Germany
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8100
- Registration Number
- NCT05285826
- Locations
- 🇨🇳
Beijing Youan Hospital ( Site 0001), Bejing, Beijing, China
🇨🇳The Second Affiliated Hospital Chongqing Medical University ( Site 0052), Chongqing, Chongqing, China
🇨🇳Southern Medical University Nanfang Hospital-Center for Drug Clinical Research ( Site 0031), Guangzhou, Guangdong, China
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 381
- Registration Number
- NCT05261126
- Locations
- 🇺🇸
Dallas Diabetes Research Center ( Site 0012), Dallas, Texas, United States
🇺🇸Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0051), Houston, Texas, United States
🇺🇸Midwest Institute For Clinical Research ( Site 0036), Indianapolis, Indiana, United States